Study guide

2.2 Cell Cycle Control, Apoptosis & Cell Signalling

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

2.2 Cell Cycle Control, Apoptosis & Cell Signalling

Key Takeaways Explain This Topic AI

p53 arrests the cell cycle at the G1/S checkpoint and triggers apoptosis; biallelic loss underlies Li-Fraumeni syndrome and most sporadic cancers.

Gs-coupled receptors raise cyclic AMP, Gq-coupled receptors generate IP3 and diacylglycerol, and Gi-coupled receptors inhibit adenylate cyclase.

Intrinsic apoptosis is mitochondrial and BCL-2 regulated; extrinsic apoptosis is triggered by Fas and TNF death receptors, and both converge on caspase activation.

Last updated: September 2026

Cell Cycle Regulation, Checkpoints & Apoptosis

The eukaryotic cell cycle progresses through four discrete phases (G1 -> S -> G2 -> M), driven by cyclic assemblies of cyclins and Cyclin-Dependent Kinases (CDKs). G1 Phase ───────────────────> S Phase ───────────────────> G2 Phase ─────────────> M Phase

  • │ │ │ │
  • [Cyclin D-CDK4/6] [Cyclin E-CDK2] [Cyclin A-CDK2] [Cyclin B-CDK1]
  • │ │ │ │
  • ▼ ▼ ▼ ▼
  • Rb Phosphorylation DNA Replication DNA Damage Check Spindle Assembly
  • (E2F Factor Release) Initiation & Progress (ATM/ATR -> Chk1/2) Checkpoint
  • Checkpoints and Tumour Suppressor Kinetics

G1/S Restriction Point : Commits the cell to cell division. Governed by the retinoblastoma tumour suppressor protein (Rb) :

Hypophosphorylated Rb (active form) binds and sequesters the E2F transcription factor , repressing genes required for DNA synthesis.

Mitogenic signals induce Cyclin D , which complexes with CDK4 and CDK6 to partially phosphorylate Rb.

Cyclin E-CDK2 complexes complete the hyperphosphorylation of Rb.

Hyperphosphorylated Rb (inactive form) dissociates from E2F. Free E2F enters the nucleus, driving transcription of thymidine kinase, DNA polymerase alpha, and Cyclin A, propelling the cell into S phase.

CDK Inhibitors (CDKIs) :

INK4 family (p15, p16, p18, p19): Selectively bind and inhibit CDK4 and CDK6. Loss of p16INK4a (via CDKN2A deletion) is frequent in melanoma, pancreatic cancer, and glioblastoma.

CIP/KIP family (p21, p27, p57): Inhibit all cyclin-CDK complexes. p21Cip1 is directly transactivated by p53 in response to DNA damage.

p53 "Guardian of the Genome" Cascade : DNA double-strand breaks activate ATM (ataxia-telangiectasia mutated) and ATR kinases, which phosphorylate p53, preventing its degradation by the E3 ubiquitin ligase MDM2 . Stable p53 accumulates as a tetrameric transcription factor that:

Transactivates p21 , inducing G1 arrest to allow enzymatic DNA repair.

Transactivates GADD45 , promoting nucleotide excision repair.

If repair fails, transactivates pro-apoptotic effectors Bax, Bak, PUMA, and Noxa , triggering apoptosis.

Li-Fraumeni Syndrome : Autosomal dominant germline mutation in TP53 on chromosome 17p13. Characterized by early-onset sarcomas (osteosarcoma, rhabdomyosarcoma), breast carcinoma, brain tumors (glioma), adrenocortical carcinoma, and leukemias (the SBLA cancer complex).

Apoptosis versus Necrosis

  • Parameter Apoptosis Necrosis
  • Mechanism Regulated, ATP-dependent programmed cell death Unregulated, accidental injury due to ATP depletion

Cell Volume Cellular shrinkage, condensation of chromatin (pyknosis) Cellular swelling (oncosis), organelle swelling

Membrane Integrity Intact; plasma membrane blebbing forming apoptotic bodies Ruptured; early loss of membrane permeability and lysis

Inflammatory Response Absent; apoptotic bodies phagocytosed by macrophages Robust; damage-associated molecular patterns (DAMPs) release

DNA Degradation Internucleosomal cleavage into 180-200 bp fragments (laddering) Non-specific, diffuse, smear-like DNA fragmentation

Molecular Cascades of Apoptosis

Intrinsic (Mitochondrial) Pathway : Triggered by cellular stress, withdrawal of survival factors, or DNA damage.

Pro-apoptotic BH3-only sensors (Bim, Bid, Bad, Puma, Noxa) neutralize anti-apoptotic Bcl-2, Bcl-xL, and Mcl-1 .

Unopposed pro-apoptotic effectors Bax and Bak oligomerise to form permeability transition pores in the outer mitochondrial membrane.

Cytochrome c leaks from the intermembrane space into the cytosol.

Cytosolic Cytochrome c binds Apaf-1 (apoptotic protease activating factor 1) in the presence of dATP, assembling a wheel-like heptameric apoptosome .

The apoptosome recruits and cleaves pro-caspase-9 (initiator caspase).

Active Caspase-9 cleaves downstream executioner caspases-3, -6, and -7 .

Bcl-2 Overexpression : In follicular lymphoma , the reciprocal translocation t(14;18)(q32;q21) juxtaposes the BCL2 proto-oncogene with the immunoglobulin heavy chain ( IGH ) promoter, causing Bcl-2 overexpression, which sequesters Bax/Bak and makes germinal centre B cells resistant to apoptosis.

Extrinsic (Death Receptor) Pathway : Triggered by extracellular death ligands.

Fas ligand (FasL / CD95L) binds Fas (CD95) , or TNF-alpha binds TNFR1 .

Trimerisation of receptor death domains recruits the adaptor protein FADD (Fas-Associated Death Domain).

FADD recruits pro-caspase-8 or pro-caspase-10 to assemble the DISC (death-inducing signaling complex).

Active Caspase-8 cleaves executioner Caspase-3 directly, and cleaves cytosolic Bid to truncated Bid (tBid) , providing cross-talk that activates the intrinsic mitochondrial pathway.

Cell Signaling & Second Messenger Pathways

Intercellular communication relies on transmembrane receptors coupling extracellular ligands to downstream metabolic and transcriptional responses.

G-Protein Coupled Receptors (GPCRs)

GPCRs are 7-transmembrane alpha-helical receptors that couple to heterotrimeric G-proteins comprising alpha, beta, and gamma subunits. Ligand binding catalyzes GDP-to-GTP exchange on the alpha subunit, dissociating G-alpha-GTP from the G-beta-gamma dimer. ┌─────────────────────────────────── GPCR Subtypes ───────────────────────────────────┐

  • │ │ │
  • ▼ ▼ ▼
  • Gs Pathway Gi Pathway Gq Pathway
  • [G-alpha-s • GTP] [G-alpha-i • GTP] [G-alpha-q • GTP]
  • │ │ │
  • ▼ ▼ ▼
  • Stimulates Adenylyl Cyclase Inhibits Adenylyl Cyclase Stimulates Phospholipase C beta
  • │ │ │
  • ▼ ▼ ▼
  • cAMP Rises cAMP Falls PIP2 ──> IP3 + DAG
  • │ │ │ │
  • ▼ ▼ ▼ ▼
  • Activates PKA Suppresses PKA Ca2+ Release Activates PKC
  • (Phosphorylates targets) (Reduced phosphorylation) (from ER/SR) │
  • ▼
  • Smooth Muscle Contraction
  • GPCR Subunit Classes and Clinical Manifestations

Gs-alpha Pathway : Ligand binding stimulates adenylyl cyclase, converting ATP to cyclic AMP (cAMP). cAMP binds regulatory subunits of Protein Kinase A (PKA) , releasing active catalytic subunits that phosphorylate serine/threonine residues on metabolic enzymes and the transcription factor CREB .

Receptors: Beta-1, Beta-2, Beta-3, V2 (renal), H2 (gastric), Glucagon, PTH, TSH, ACTH, Calcitonin, GHRH .

Cholera Toxin : Produced by Vibrio cholerae ; catalyzes ADP-ribosylation of Gs-alpha, abolishing its intrinsic GTPase activity. Gs-alpha is locked in an active state, causing uncontrolled cAMP production in intestinal enterocytes, massive PKA-mediated opening of CFTR channels, and voluminous watery "rice-water" diarrhea.

Gi-alpha Pathway : Ligand binding inhibits adenylyl cyclase, decreasing cAMP production and suppressing PKA activity.

Receptors: Alpha-2, M2 (cardiac), D2 (dopamine) .

Pertussis Toxin : Produced by Bordetella pertussis ; catalyzes ADP-ribosylation of Gi-alpha, locking it in the inactive, GDP-bound state. Inactivated Gi can no longer inhibit adenylyl cyclase, causing high intracellular cAMP that impairs leukocyte chemotaxis, producing severe lymphocytosis.

Gq-alpha Pathway : Ligand binding stimulates Phospholipase C beta (PLC-beta) , which cleaves membrane phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers:

Inositol 1,4,5-trisphosphate (IP3) : Diffuses to the sarcoplasmic/endoplasmic reticulum, binding IP3-gated Ca2+ channels to release Ca2+ into the cytoplasm.

Diacylglycerol (DAG) : Remains membrane-bound and, together with released Ca2+, activates Protein Kinase C (PKC) .

Receptors ( "HAVe 1 M&M" ): H1, Alpha-1, V1 (vascular), M1, M3 .

Receptor Tyrosine Kinases (RTKs) and Intrinsic Kinase Cascades

Structure and Activation : Single-pass transmembrane receptors with intrinsic cytosolic tyrosine kinase domains (insulin receptor, IGF-1, EGFR, PDGF, VEGF, FGF). Ligand binding induces receptor dimerisation, activating trans-autophosphorylation of tyrosine residues within the cytosolic tail.

Downstream Pathways :

Ras-Raf-MEK-ERK (MAPK) Pathway : Phosphotyrosines recruit SH2-domain adaptor proteins (GRB2) complexed with Sos (guanine nucleotide exchange factor). Sos converts inactive Ras-GDP to active Ras-GTP . Active Ras recruits and activates Raf kinase, which phosphorylates MEK, which in turn phosphorylates ERK (extracellular signal-regulated kinase) . Activated ERK translocates to the nucleus to induce transcription of c-Myc and c-Fos , driving cellular proliferation.

PI3K-Akt-mTOR Pathway : Phosphotyrosines recruit Phosphoinositide 3-kinase (PI3K) , which converts PIP2 to PIP3. Membrane PIP3 recruits Akt (Protein Kinase B) and PDK1. Activated Akt phosphorylates Bad (inhibiting apoptosis) and stimulates mTOR (mammalian target of rapamycin), promoting protein synthesis, cell growth, and angiogenesis. The lipid phosphatase PTEN dephosphorylates PIP3 back to PIP2; loss-of-function PTEN mutations drive unrestrained Akt activation in Cowden syndrome and endometrial carcinoma.

Non-Receptor Tyrosine Kinases (JAK-STAT) : Receptors for cytokines, growth hormone, prolactin, erythropoietin, and thrombopoietin lack intrinsic kinase activity. Ligand binding induces receptor oligomerisation, cross-activating associated Janus kinases (JAK1, JAK2, JAK3, TYK2) . Activated JAKs phosphorylate receptor tyrosine residues, creating docking sites for STATs (Signal Transducers and Activators of Transcription). Phosphorylated STATs dimerise, dissociate, and translocate directly to the nucleus as active transcription factors. The gain-of-function JAK2 V617F mutation produces autonomous STAT phosphorylation, driving BCR-ABL-negative myeloproliferative neoplasms (polycythaemia vera, essential thrombocythaemia, primary myelofibrosis).

Cyclic GMP / Nitric Oxide Cascade : Endothelial nitric oxide synthase (eNOS) synthesizes nitric oxide (NO) from L-arginine. NO diffuses into adjacent vascular smooth muscle cells and binds the heme moiety of soluble guanylyl cyclase (sGC) , converting GTP to cyclic GMP (cGMP) . Elevated cGMP activates Protein Kinase G (PKG) , which phosphorylates phospholamban and myosin light-chain phosphatase, promoting Ca2+ sequestration and smooth muscle relaxation. Atrial and B-type natriuretic peptides (ANP, BNP) stimulate a transmembrane, particulate guanylyl cyclase receptor (NPR-A). cGMP is degraded to 5'-GMP by phosphodiesterase-5 (PDE5) , which is selectively inhibited by sildenafil and tadalafil to prolong vasodilation.